gRNA Market Size & Growth Forecast 2027–2036, By Segments (End-use, gRNA Type, Product & Services, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
gRNA Market size was estimated at USD 793.9 million in 2026 and is projected to grow at a 17.86% CAGR from 2027 to 2036, surpassing USD 4.11 billion by 2036. The industry revenue for 2027 is assessed at USD 913.3 million.
Get more details on this report
Request Free Sample ReportgRNA Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 55.02% share supported by strong gene editing ecosystem, dense biotech and pharmaceutical presence, and aligned research workflows across academic and commercial sectors.
- Asia Pacific expands at 20.83% CAGR driven by rising biotechnology investment, expanding genome editing research, broader laboratory adoption, and increasing demand for guide RNA tools.
Segment Momentum
- Pharmaceutical & Biotechnology Companies held a 52.26% share in 2026, driven by commercial use of gRNA in therapeutic discovery, gene-editing development, and scalable procurement aligned with drug development workflows.
- GMP-grade demand is rising fastest as development programs advance toward clinical and regulated manufacturing, increasing the need for compliance-ready gRNA suitable for later-stage therapeutic applications.
Market Expansion Drivers
- Expanding CRISPR-based genome editing applications accelerating demand for precision gRNA solutions.
- Increasing pharmaceutical and biotechnology investments driving gene editing research commercialization.
- Rising agricultural biotechnology adoption supporting gene-edited crop development initiatives.
Leading Market Participants
- Top players in the gRNA market include Thermo Fisher Scientific Inc. (United States), Merck KGaA (Germany), Agilent Technologies, Inc. (United States), Takara Bio Inc. (Japan), Synthego Corporation (United States), Azenta Life Sciences, Inc. (United States), Jena Bioscience GmbH (Germany), System Biosciences, LLC (United States), Synbio Technologies Co., Ltd. (China), Revvity, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 793.9 million
- 2027 Estimated Market Size: USD 913.3 million.
- Projected Market Size: USD 4.11 billion by 2036
- Growth Forecast: 17.86% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Pharmaceutical & Biotechnology Companies (End-use) | Research-Use (gRNA Type) | Products (Product & Services) | Genome Engineering (Application)
- Emerging Opportunity Segment: Academic Research Institutes (End-use) | GMP-grade (gRNA Type) | Custom gRNA Synthesis Services (Product & Services) | Genome Engineering (Application)
Market Growth Drivers and Industry Trends
Expanding CRISPR-based genome editing applications accelerating demand for precision gRNA solutions
The growing use of CRISPR-based genome editing across research and therapeutic development is increasing the need for guide RNA sequences designed to target specific genetic locations. The gRNA market is supported by this expansion because precise guide selection is fundamental to the performance and specificity of CRISPR-based editing workflows. Wider application of genome editing in gene function studies, disease research, and therapeutic development is therefore increasing demand for customized and application-specific gRNA solutions.
Increasing pharmaceutical and biotechnology investments driving gene editing research commercialization
Greater investment in pharmaceutical and biotechnology research is accelerating the transition of gene editing technologies from laboratory investigation toward commercial development. This trend is strengthening the gRNA market as research organizations require reliable guide RNA solutions for target validation, genetic modification, screening, and development of potential therapeutic applications. Increased funding for advanced biological research is also supporting the development of more sophisticated gene editing workflows.
Rising agricultural biotechnology adoption supporting gene-edited crop development initiatives
Agricultural biotechnology is increasingly using gene editing to investigate crop traits related to productivity, resilience, quality, and other agronomic characteristics. The gRNA market is benefiting from this adoption because CRISPR-based crop modification requires precisely designed guide RNAs to target selected genetic sequences. Expanding research into gene-edited crops is increasing the use of specialized genome editing tools across plant science and agricultural biotechnology programs.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding CRISPR-based genome editing applications accelerating demand for precision gRNA solutions | 2.00% | High | North America, Europe | High | Near Term |
| Increasing pharmaceutical and biotechnology investments driving gene editing research commercialization | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Rising agricultural biotechnology adoption supporting gene-edited crop development initiatives | 1.50% | Moderate | Asia Pacific, Latin America | Emerging | Long Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the gRNA market with a 55.02% share in 2026, reflecting the region's strong position in gene-editing research, advanced biotechnology infrastructure, and substantial investment in genomic medicine. Extensive academic and research capabilities support continued development of CRISPR-based technologies, while growing activity in therapeutic discovery and precision medicine is creating demand for sophisticated guide RNA design and synthesis solutions. The region also benefits from an established ecosystem for molecular biology research and a regulatory environment that supports innovation in advanced genetic technologies. Increasing exploration of gene-editing applications across research and therapeutic development is strengthening the strategic importance of gRNA technologies.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, fueled by expanding biotechnology research, increasing investment in genomics, and growing adoption of gene-editing techniques within academic and pharmaceutical research. Improvements in laboratory infrastructure and the development of local biotechnology capabilities are enabling broader access to advanced molecular tools. Researchers are increasingly applying CRISPR technologies across areas such as therapeutic development, functional genomics, agriculture, and disease research, widening the potential user base for gRNA products. Support for biotechnology innovation and rising demand for precision research tools are expected to further accelerate regional uptake.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants/StartupsiScaleLowMedium High | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Precision Manufacturing FocusGermany emphasizes high-quality nucleic acid manufacturing and standardized production processes to support expanding gRNA research. The country strengthens commercial opportunities by integrating advanced laboratory capabilities with pharmaceutical and biotechnology development activities.
France 🇫🇷
Genomic Research IntegrationFrance strengthens the gRNA market by integrating genomic research with academic and clinical innovation programs. French biotechnology organizations increasingly explore gRNA applications that support functional genomics, molecular biology, and therapeutic development activities.
Italy 🇮🇹
Academic Research CollaborationItaly advances the gRNA market through collaborative research networks connecting universities, biomedical institutes, and biotechnology companies. Italian organizations prioritize laboratory innovation and specialized research projects that expand applications for gene-editing technologies.
Japan 🇯🇵
Therapeutic Innovation PipelineJapan advances the gRNA market through investments in gene-editing research and precision medicine initiatives. Japanese organizations increasingly integrate gRNA technologies into drug discovery workflows while emphasizing quality, regulatory compliance, and translational research.
South Korea 🇰🇷
Biotech Commercial ExpansionSouth Korea supports gRNA adoption by expanding biotechnology innovation and scalable life science manufacturing capabilities. The country's growing focus on genomic technologies encourages partnerships that accelerate research commercialization and product development.
United States 🇺🇸
Translational Research HubThe U.S. continues to prioritize gRNA applications through strong biotechnology research, clinical development, and platform innovation. Collaboration between research institutions, biotechnology companies, and pharmaceutical developers supports broader use of gRNA technologies across therapeutic and functional genomics programs.
gRNA Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest Segment) vs Academic Research Institutes (Fastest-Growing Segment)
Pharmaceutical & biotechnology companies held the largest share of 52.26% in 2026 in the gRNA market, reflecting the extensive use of guide RNA technologies in gene-editing research, therapeutic development, target validation, and related biotechnology applications. These organizations increasingly rely on gRNA to support precise manipulation of genetic sequences and accelerate development workflows involving advanced genomic technologies. The expanding focus on targeted therapies and gene-based approaches is strengthening the importance of reliable and application-specific gRNA solutions. Greater investment in translational research and the development of sophisticated gene-editing platforms further supports demand from pharmaceutical and biotechnology organizations.
Academic research institutes represent the fastest-growing end-use segment as universities and research centers increasingly adopt gene-editing technologies for fundamental biological studies and exploratory research. gRNA enables researchers to investigate gene function, cellular mechanisms, disease pathways, and genetic interactions with greater precision, making it valuable across a broad range of research programs. Increasing accessibility of gene-editing tools and the expansion of molecular biology research are encouraging wider adoption within academic environments. The growing use of advanced genomic methods in basic and translational research is consequently supporting rapid expansion of gRNA demand among academic institutions.
gRNA Type Segment Analysis: Research-Use (Largest Segment) vs GMP-grade (Fastest-Growing Segment)
Research-use gRNA held the largest share in 2026, supported by its broad application across laboratory research, gene-function studies, experimental gene editing, and early-stage development activities. The extensive use of gene-editing technologies in discovery and exploratory research creates sustained demand for gRNA products designed for laboratory applications. Researchers require flexible and accessible tools for evaluating genetic targets and developing experimental protocols, supporting the continued prominence of research-use gRNA. Expansion of genomic research and increasing experimentation with CRISPR-based approaches further reinforce its position within the gRNA type landscape.
GMP-grade gRNA is expected to be the fastest-growing type as the development of gene-based therapeutics increasingly requires materials that meet stringent manufacturing and quality requirements. As gene-editing research advances toward more clinically oriented applications, demand is growing for gRNA produced under controlled standards appropriate for regulated development environments. The increasing focus on reproducibility, traceability, consistency, and manufacturing quality is supporting adoption of GMP-grade materials. This transition from exploratory research toward more advanced therapeutic development is creating stronger opportunities for high-quality gRNA products suitable for regulated applications.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Pharmaceutical & Biotechnology Companies, Academic Research Institutes, CMOs & CROs | Pharmaceutical & Biotechnology Companies | Academic Research Institutes |
| gRNA Type | Research-Use, GMP-grade | Research-Use | GMP-grade |
| Product & Services | Products, Custom gRNA Synthesis Services | Products | Custom gRNA Synthesis Services |
| Application | Genome Engineering, Disease Model Studies, Functional Genomics, Epigenetics, Others | Genome Engineering | Genome Engineering |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Major players in the gRNA market:
1. Thermo Fisher Scientific Inc. (United States)
2. Merck KGaA (Germany)
3. Agilent Technologies Inc. (United States)
4. Takara Bio Inc. (Japan)
5. Synthego Corporation (United States)
6. Azenta Life Sciences Inc. (United States)
7. Jena Bioscience GmbH (Germany)
8. System Biosciences LLC (United States)
9. Synbio Technologies Co. Ltd. (China)
10. Revvity Inc. (United States)
The gRNA market is advancing rapidly through intensive research efforts focused on improving gene-editing accuracy and efficiency. Emerging technology platforms are enhancing delivery mechanisms and molecular stability. Collaborative research frameworks are strengthening innovation pipelines, while new product developments reflect growing capability in precision genetic engineering applications across biomedical research and therapeutic development.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Merck KGaA (Germany) | |||||||
| Agilent Technologies Inc. (United States) | |||||||
| Takara Bio Inc. (Japan) | |||||||
| Synthego Corporation (United States) | |||||||
| Azenta Life Sciences Inc. (United States) | |||||||
| Jena Bioscience GmbH (Germany) | |||||||
| System Biosciences LLC (United States) | |||||||
| Synbio Technologies Co. Ltd. (China) | |||||||
| Revvity Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Cirena | May-26 | Cirena entered a licensing agreement for Agilent Technologies’ long RNA purification technology. The partnership enables the scalable production of high-purity 100–300 nucleotide RNA constructs, expanding industrial capabilities for supplying crucial guide RNA materials required in advanced CRISPR genome editing applications. |
| Synthego | Jul-25 | Synthego completed its acquisition by Perceptive Advisors. The transaction secures necessary financial resources to scale the company's CRISPR offerings, directly impacting the guide RNA manufacturing segment by stabilizing and accelerating production of high-quality gene-editing products. |
| Integrated DNA Technologies (IDT) | Jul-25 | Integrated DNA Technologies expanded its translational CRISPR portfolio by introducing clinical-grade, high-purity guide RNAs alongside specialized off-target analysis services. This development scales the company's operational infrastructure to address strict regulatory workflows and growing commercial demand for therapeutic gene-editing solutions. |
| Synthego | May-25 | Synthego filed for Chapter 11 bankruptcy protection due to mounting financial pressures from intensive research investments and debt obligations. The restructuring process involves debtor-in-possession financing and a stalking horse credit bid, altering competitive dynamics within the commercial guide RNA market. |
| GenScript | Dec-24 | The United States FDA granted IND approval for Base Therapeutics’ base-edited NK cell therapy, which incorporates GenScript’s cGMP-grade single guide RNA (sgRNA). The regulatory milestone validates the commercial viability and supply chain safety of the manufacturing processes for therapeutic-grade guide RNA. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
gRNA Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Customization Level | Off-the-Shelf gRNA, Sequence-Customized gRNA, Fully Custom-Designed gRNA |
| Manufacturing Scale | Research Scale, Preclinical Scale, Clinical and Commercial Scale |
| Pricing Model | Per-Sequence Pricing, Volume-Based Pricing, Project-Based Pricing, Subscription or Contract-Based Pricing |
gRNA Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Therapeutic Pipeline Commercial Opportunity Assessment |
|
| Technology Platform Licensing and Collaboration Landscape |
|
| Research-to-Commercialization Adoption Assessment |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much is the gRNA market worth?
How is the gRNA industry projected to perform over the next decade?
How is expanding CRISPR adoption influencing demand for precision gRNA solutions?
How are pharmaceutical and biotechnology investments changing procurement patterns in the gRNA market?
Why do Pharmaceutical & Biotechnology Companies dominate the gRNA market?
Why is GMP-grade the fastest-growing gRNA type?
Why does North America lead the gRNA market?
What is driving growth in Asia Pacific gRNA market?
What are the key competitors in the gRNA landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook